CA2261793A1 - Phosphatase inhibitors and methods of use thereof - Google Patents

Phosphatase inhibitors and methods of use thereof Download PDF

Info

Publication number
CA2261793A1
CA2261793A1 CA002261793A CA2261793A CA2261793A1 CA 2261793 A1 CA2261793 A1 CA 2261793A1 CA 002261793 A CA002261793 A CA 002261793A CA 2261793 A CA2261793 A CA 2261793A CA 2261793 A1 CA2261793 A1 CA 2261793A1
Authority
CA
Canada
Prior art keywords
segment
compound
bivalent
compounds
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002261793A
Other languages
English (en)
French (fr)
Inventor
Robert L. Rice
April Cunningham
Peter Wipf
John S. Lazo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2261793A1 publication Critical patent/CA2261793A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002261793A 1996-07-30 1997-07-30 Phosphatase inhibitors and methods of use thereof Abandoned CA2261793A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/688,530 1996-07-30
US08/688,530 US5700821A (en) 1996-07-30 1996-07-30 Phosphatase inhibitors and methods of use thereof
PCT/US1997/013408 WO1998004257A1 (en) 1996-07-30 1997-07-30 Phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2261793A1 true CA2261793A1 (en) 1998-02-05

Family

ID=24764793

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002261793A Abandoned CA2261793A1 (en) 1996-07-30 1997-07-30 Phosphatase inhibitors and methods of use thereof

Country Status (8)

Country Link
US (4) US5700821A (OSRAM)
EP (1) EP0959884A1 (OSRAM)
JP (1) JP3268782B2 (OSRAM)
AR (1) AR008120A1 (OSRAM)
AU (1) AU715546B2 (OSRAM)
CA (1) CA2261793A1 (OSRAM)
IL (1) IL128217A0 (OSRAM)
WO (1) WO1998004257A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121973A1 (en) * 2002-02-05 2004-06-24 Monia Brett P Antisense modulation of protein phosphatase 2 Catalytic subunit alpha expression
US6465250B1 (en) 2001-02-09 2002-10-15 Isis Pharmaceuticals, Inc. Antisense modulation of protein phosphatase 2 catalytic subunit alpha expression
US6602713B1 (en) * 2001-02-09 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
US7244622B2 (en) * 1996-04-03 2007-07-17 Applera Corporation Device and method for multiple analyte detection
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6277566B1 (en) * 1998-02-13 2001-08-21 Phillip A. Beachy Method for identifying a hedgehog-mediated phosphorylation state dependent transcription factor
JP2002512811A (ja) * 1998-04-27 2002-05-08 ユニバーシティー ヘルス ネットワーク 遺伝子スクリーニング法及び関連アッセイ法
US7051360B1 (en) * 1998-11-30 2006-05-23 United Video Properties, Inc. Interactive television program guide with selectable languages
US7238711B1 (en) * 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
EP1146909A4 (en) * 1999-02-03 2004-12-29 Univ Johns Hopkins Method of treating cancer by restoration of pp32 function
AU6396600A (en) * 1999-08-04 2001-03-05 Chemrx Advanced Technologies, Inc. Solid phase synthesis of oxa- and thiazoles
AU7077400A (en) * 1999-08-31 2001-03-26 Basf Aktiengesellschaft Method of identifying inhibitors of cdc25
AU1073001A (en) * 1999-10-12 2001-04-23 Basf Aktiengesellschaft Method of identifying inhibitors of cdc25
AU2001227812A1 (en) 2000-05-02 2001-11-12 Advanced Syntech, Llc A Kentucky Limited Liability Corporation A novel solid support template for preparation of highly functionalized heterocycle compounds
US20030027308A1 (en) * 2000-05-30 2003-02-06 Sugen Incorporated Novel human protein phosphatases identified from genomic sequencing
FR2812945B1 (fr) * 2000-08-10 2002-10-04 Aventis Pharma Sa Utilisation de la proteine grf1 et cellules exprimant la proteine grf1 pour le criblage de molecules
US20040157306A1 (en) * 2000-11-13 2004-08-12 Sugen Incorporated Mammalian protein phosphatases
WO2002070680A1 (en) * 2001-03-01 2002-09-12 Basf Aktiengesellschaft Method of identifying inhibitors of cdc25
US20030120073A1 (en) * 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
US20030124590A1 (en) * 2001-10-16 2003-07-03 Kosaku Uyeda Carbohydrate response element binding protein and uses thereof
WO2003042390A1 (en) * 2001-11-13 2003-05-22 Sugen, Inc. Mammalian protein phosphatases
EP1483283A4 (en) * 2002-03-13 2007-04-11 Signum Biosciences Inc MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
US20050074831A1 (en) * 2002-03-19 2005-04-07 Jasna Jerecic Interaction of NMDA receptor with protein serine threonine phosphatases
US20040023382A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of PPP3CB expression
US6828149B2 (en) 2002-06-20 2004-12-07 Isis Pharmaceuticals, Inc. Antisense modulation of PPP3R1 expression
JP2006514821A (ja) * 2002-06-25 2006-05-18 セローノ ジェネティクス インスティテュート ソシエテ アノニム 新規なｋｃｎｑポリペプチド、それらのモジュレータ及び精神障害の治療におけるそれらの使用
AU2003270218B2 (en) * 2002-10-02 2008-11-20 Sanofi-Aventis Deutschland Gmbh Hydroxyphenylundecane derivatives, a process for their production and their use
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE102006033321A1 (de) * 2006-07-17 2008-01-24 Westfälische Wilhelms-Universität Münster Medizinische Verwendung von N-Phenylpropenoyl-Aminosäurederivaten und verwandten Verbindungen
KR100980328B1 (ko) * 2007-12-14 2010-09-06 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는트리아졸릴-티오-에타논 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 암 예방 및 치료용조성물
EP2282735B1 (en) 2008-04-21 2019-01-16 Signum Biosciences, Inc. Pp2a modulators for treating alzheimer, parkinson, diabetes
CR20240513A (es) 2022-04-22 2025-04-30 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
CN119454697B (zh) * 2025-01-07 2025-04-08 首都医科大学附属北京地坛医院 一种小分子化合物在制备抗肝损伤或抗肝纤维化药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5280034A (en) * 1991-08-23 1994-01-18 E. R. Squibb & Sons, Inc. Bis-heterocyclic prostaglandin analogs
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5770620A (en) * 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors

Also Published As

Publication number Publication date
IL128217A0 (en) 1999-11-30
US5925660A (en) 1999-07-20
AU3820597A (en) 1998-02-20
AU715546B2 (en) 2000-02-03
WO1998004257A1 (en) 1998-02-05
EP0959884A1 (en) 1999-12-01
US5700821A (en) 1997-12-23
AR008120A1 (es) 1999-12-09
JP2000515165A (ja) 2000-11-14
EP0959884A4 (OSRAM) 1999-12-15
US6040323A (en) 2000-03-21
US5856506A (en) 1999-01-05
JP3268782B2 (ja) 2002-03-25

Similar Documents

Publication Publication Date Title
AU715546B2 (en) Phosphatase inhibitors and methods of use thereof
US6506781B1 (en) Oxazole PPAR antagonist
EP2744807A1 (en) Lysophosphatidic acid receptor antagonists
Wipf et al. Combinatorial synthesis and biological evaluation of library of small-molecule Ser/Thr-protein phosphatase inhibitors
US6576766B1 (en) Signal transduction inhibitors, compositions containing them
JP2007516434A (ja) リポキシン受容体ｆｐｒｌ１の、疼痛および炎症の治療に有効な化合物を識別する手段としての使用
Fatima et al. Synthesis, molecular docking and xanthine oxidase inhibitory activity of 5-aryl-1H-tetrazoles
RU2268262C2 (ru) Производные дигидронафталина и лекарственное средство, включающее указанные производные в качестве активного ингредиента
WO2002036580A9 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
Chen et al. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1
Kozikowski et al. Synthesis, molecular modeling, 2-D NMR, and biological evaluation of ILV mimics as potential modulators of protein kinase C
Wang et al. Design, synthesis and anticancer activity of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-1, 2, 3-thiadiazoles as microtubule-destabilizing agents
CS199568B2 (en) Method of producing substituted derivatives of alpha aminooxycarboxylic acids hydrazides and addition salts thereof with acids
KR20150079616A (ko) 암 치료를 위한 베타-하이드록실라제의 억제제
Jadeja et al. Synthesis, type II diabetes inhibitory activity and docking studies of novel thiazole molecules
US9399653B2 (en) Methods and systems for preparing irreversible inhibitors of protein tyrosine phosphatases
US7317030B2 (en) Compounds as inhibitors of cell proliferation and viral infections
JPH07126286A (ja) 新規なペプチド誘導体
Lazo Novel Combinatorial Chemistry-Derived Inhibitors of Oncogenic Phosphatases.
WO2021082181A1 (zh) Set8赖氨酸甲基转移酶抑制剂及其制备方法和用途
Wipf et al. Synthesis and biological evaluation of a targeted library of protein phosphatase inhibitors
EP1718623B1 (en) Compounds as inhibitors of cell proliferation and viral infections
Dan et al. Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and-5
Yin Novel Small Molecule Probes and Quantification of Binding to C1 Domains of Protein Kinase C in Living Cells
CN120965805A (zh) 一种磷酸化拟肽类化合物及其医药用途

Legal Events

Date Code Title Description
FZDE Discontinued